FINWIRES · TerminalLIVE
FINWIRES

Evercore ISI Downgrades Ultragenyx Pharmaceutical to In Line From Outperform, Adjusts Price Target to $16 From $34

By

Ultragenyx Pharmaceutical (RARE) has an average rating of overweight and mean price target of $33.95, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Related Articles

Research

Investec Starts Krishna Institute of Medical Sciences at Buy with INR1,000 Price Target

Krishna Institute of Medical Sciences (NSE:KIMS, BOM:543308) has an average rating of buy and mean price target of 873.40 Indian rupees, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

BOM:543308NSE:KIMS
Research

RBC Capital Markets Starts Deep Yellow at Outperform with AU$2.05 Price Target

Deep Yellow (ASX:DYL) has an average rating of overweight and mean price target of AU$2.01, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

ASX:DYL
Research

Maybank Upgrades Charoen Pokphand Indonesia to Buy from Hold; Price Target is IDR3,500

Charoen Pokphand Indonesia (IDX:CPIN) has an average rating of overweight and mean price target of 4,243.33 rupiah, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

IDX:CPIN